Intervacc appoints international bacteriology expert as Chief Scientific Officer
Stockholm 11 June 2020 – The Swedish biotechnology company Intervacc AB (publ), which is developing modern, effective and safe vaccines for animal health has appointed Dr. Andrew Waller as the new Chief Scientific Officer, CSO. The company has thus appointed an international leader in bacterial research in veterinary species to lead the company's exciting development program for vaccines based on recombinant proteins. This appointment follows on the success of Intervacc’s lead vaccine project against strangles in horses, Strangvac, which was evaluated by Andrew’s former laboratory at the